• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

David P. Harrington, PhD


  • Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy GF, Qureshi AA, Schmults CD.Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma.J Clin Oncol. 2014 Feb 1;32(4):327-34.
  • Loong B, Zaslavsky AM, He Y, Harrington DP.Disclosure control using partially synthetic data for large-scale health surveys, with applications to CanCORS.Stat Med. 2013 May 13.
  • Schwede M, Spentzos D, Bentink S, Hofmann O, Haibe-Kains B, Harrington D, Quackenbush J, Culhane AC.Stem Cell-Like Gene Expression in Ovarian Cancer Predicts Type II Subtype and Prognosis.PLoS ONE. 2013;8(3):e57799.
  • Blinder VS, Norris VW, Peacock NW, Griggs JJ, Harrington DP, Moore A, Theriault RL, Partridge AH, .Patient perspectives on breast cancer treatment plan and summary documents in community oncology care: a pilot program.Cancer. 2013 Jan 1;119(1):164-72.
  • He Y, Zaslavsky A, Landrum M, Harrington D, Catalano P.Multiple imputation in a large-scale complex survey: a practical guide.Statistical Methods in Medical Research. 2010 Dec;19(6):653-70.
  • Ayanian JZ, Zaslavsky AM, Arora NK, Kahn KL, Malin JL, Ganz PA, van Ryn M, Hornbrook MC, Kiefe CI, He Y, Urmie JM, Weeks JC, Harrington DP.Patients' Experiences With Care for Lung Cancer and Colorectal Cancer: Findings From the Cancer Care Outcomes Research and Surveillance Consortium.J Clin Oncol. 2010 Sep 20;28(27):4154-61.
  • Kahn KL, Adams JL, Weeks JC, Chrischilles EA, Schrag D, Ayanian JZ, Kiefe CI, Ganz PA, Bhoopalam N, Potosky AL, Harrington DP, Fletcher RH.Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer.JAMA. 2010 Mar 17;303(11):1037-45.
  • Chrischilles EA, Pendergast JF, Kahn KL, Wallace RB, Moga DC, Harrington DP, Kiefe CI, Weeks JC, West DW, Zafar SY, Fletcher RH.Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer.J Clin Oncol. 2010 Feb 1;28(4):620-7.
  • Xu R, Vaida F, Harrington DP.Using profile likelihood for semiparametic model selection with application to proportional hazards mixed models.Statistica Sinica.(19):819-842.
  • Harrington D, Gail MH.Lifetime data analysis. Editorial.Lifetime Data Analysis. 2008 Mar;14(1):1-5.
  • Soh CH, Harrington DP, Zaslavsky AM.Reducing bias in parameter estimates from stepwise regression in proportional hazards regression with right-censored data.Lifetime Data Analysis. 2008 Mar;14(1):65-85.
  • Evans D, Miner T, Iannitti D, Akerman P, Cruff D, Maia-Acuna C, Harrington D, Habr F, Chauhan B, Berkenblit A, Stuart K, Sears D, Kennedy T, Safran H.Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study.Cancer Invest. 2007 Sep;25(6):445-8.
  • Laframboise T, Harrington D, Weir BA.PLASQ: A Generalized Linear Model-Based Procedure to Determine Allelic Dosage in Cancer Cells from SNP Array Data.Biostatistics. 2007 Apr;8(2):323-36.
  • Malin JL, Ko C, Ayanian JZ, Harrington D, Nerenz DR, Kahn KL, Ganther-Urmie J, Catalano PJ, Zaslavsky AM, Wallace RB, Guadagnoli E, Arora NK, Roudier MD, Ganz PA.Understanding cancer patients' experience and outcomes: development and pilot study of the Cancer Care Outcomes Research and Surveillance patient survey.Support Care Cancer. 2006 Aug;14(8):837-48.
  • Colla J, Buka S, Harrington DP, Murphy JM.Depression and modernization: a cross-cultural study of women.Soc Psychiatry Psychiatr Epidemiol. 2006 May;41(4):271-279.
  • LaFramboise T, Weir BA, Zhao X, Beroukhim R, Li C, Harrington D, Sellers WR, Meyerson M.Allele-specific amplification in cancer revealed by SNP array analysis.PLoS Comput Biol. 2005 Nov;1(6):e65.
  • Tsai JY, Iannitti D, Berkenblit A, Akerman P, Nadeem A, Rathore R, Harrington D, Roye D, Miner T, Barnett JM, Maia C, Stuart K, Safran H.Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.Am J Clin Oncol. 2005 Aug;28(4):329-33.
  • Ayanian JZ, Chrischilles EA, Wallace RB, Fletcher RH, Fouad MN, Kiefe CI, Harrington DP, Weeks JC, Kahn KL, Malin JL, Lipscomb J, Potosky AL, Provenzale DT, Sandler RS, Van Ryn M, West DW.Understanding cancer treatment and outcomes: the cancer care outcomes research and surveillance consortium.J Clin Oncol. 2004 Aug 1;22(15):2992-6.
  • Joffe S, Harrington DP, George SL, Emanuel EJ, Budzinski LA, Weeks JC.Satisfaction of the uncertainty principle in cancer clinical trials: retrospective cohort analysis.BMJ. 2004 Jun 19;328(7454):1463.
  • Huang J, Harrington D.Penalized partial likelihood regression for right-censored data with bootstrap selection of the penalty parameter.Biometrics. 2002 Dec;58(4):781-91.
  • Chen MH, Harrington DP.Bayesian cure rate models for malignant melanoma: a case-study of Eastern Cooperative Oncology Group Trial E1690.Journal of Royal Statistical Society: Series C (Applied Statistics). 2002 May;51(2):135-150.
  • Xu R, Harrington DP.A semiparametric estimate of treatment effects with censored data.Biometrics. 2001 Sep;57(3):875-85.
  • Jones CL, Harrington DP.Omnibus tests of the martingale assumption in the analysis of recurrent failure time data.Lifetime Data Anal. 2001 Jun;7(2):157-71.
  • Bernardo MV, Harrington DP.Sample size calculations for the two-sample problem using the multiplicative intensity model.Stat Med. 2001 Feb 28;20(4):557-79.
  • Harrington DP.The randomized clinical trial.Journal of American Statistical Association. 2000 Mar 01;95:312-315.
  • Bernardo MVP, Lipsitz SR, Harrington DP, Catalano PJ.Sample size calculations for failure time random variables in non-randomize studies.The Statistician. 2000 Mar;49(1):31-40.
  • Harrington DP.The tea leaves of small trials.J Clin Oncol. 1999 May;17(5):1336-8.
  • Rogus JJ, Harrington DP, Jorgenson E, Xu X.Effectiveness of extreme discordant sib pairs to detect oligogenic disease loci.Genet Epidemiol. 1997;14(6):879-84.
  • Harrington DP, Whittemore AS.Defining, identifying, and studying high-risk families: developing cohorts for epidemiologic study.J Natl Cancer Inst Monogr. 1995(17):91-4.
  • Lipsitz SR, Laird NM, Harrington DP.Weighted least squares analysis of repeated categorical measurements with outcomes subject to nonresponse.Biometrics. 1994 Mar;50(1):11-24.
  • Lipsitz SR, Laird NM, Harrington DP.Maximum likelihood regression methods for paired binary data.Stat Med. 1990 Dec;9(12):1517-25.
  • Lipsitz SR, Harrington DP.Analyzing correlated binary data using SAS.Comput Biomed Res. 1990 Jun;23(3):268-82.
  • Gilchrist KW, Harrington DP, Wolf BC, Neiman RS.Statistical and empirical evaluation of histopathologic reviews for quality assurance in the Eastern Cooperative Oncology Group.Cancer. 1988 Sep 1;62(5):861-8.
  • Kalish LA, Harrington DP.Efficiency of balanced treatment allocation for survival analysis.Biometrics. 1988 Sep;44(3):815-21.
  • O'Connell MJ, Harrington DP, Earle JD, Johnson GJ, Glick JH, Neiman RS, Silverstein MN.Chemotherapy followed by consolidation radiation therapy for the treatment of clinical stage II aggressive histologic type non-Hodgkin's lymphoma.Cancer. 1988 May 1;61(9):1754-8.
  • Cassileth PA, Harrington DP, Hines JD, Oken MM, Mazza JJ, McGlave P, Bennett JM, O'Connell MJ.Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia.J Clin Oncol. 1988 Apr;6(4):583-7.
  • O'Connell MJ, Harrington DP, Earle JD, Johnson GJ, Glick JH, Carbone PP, Creech RH, Neiman RS, Mann RB, Silverstein MN.Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.J Clin Oncol. 1987 Sep;5(9):1329-39.
  • Ezdinli EZ, Harrington DP, Kucuk O, Silverstein MW, Anderson J, O'Connell MJ.The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma.Cancer. 1987 Jul 15;60(2):156-60.